Clinical Study of Yijing Yangxue Formula Combined with Ginger-partitioned Moxibustion for Myelosuppression Induced by Platinum-based Chemotherapy in Stage III-IV Lung Cancer

INTERVENTION: Control Group:chemotherapy + conventional Western medicine supportive therapy;Treatment group:Yijing Yangxue Decoction + Moxibustion with ginger‐separated + chemotherapy + conventional Western medical supportive therapy; CONDITION: Myelosuppression after chemotherapy PRIMARY OUTCOME: Absolute neutrophil count; SECONDARY OUTCOME: White blood cell count;Platelet Reduction Rate;Myelosuppression Grading Improvement Rate;The duration of grade =3 ANC decrease in the second cycle of chemotherapy.;The lowest ANC value during the first chemotherapy cycle.;The time required for the lowest ANC value in each cycle to reach above 1.8×10^9/L.;The incidence rate of fever and neutropenia (FN);Quality of Life Rating;TCM symptom score; INCLUSION CRITERIA: (1) Aged 18–75 years, regardless of gender; (2) Patients with pathologically or cytologically confirmed stage III–IV lung cancer; (3) Scheduled to receive first‐line platinum‐based chemotherapy; (4) Expected survival = 3 months; (5) Platelet count = 90 × 109/L; (6) Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score: 0–2; (7) Voluntary participation in the study with signed informed consent.